This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Prothena Reports Second Quarter 2013 Financial Results

DUBLIN, Ireland, Aug. 12, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today reported financial results for the second quarter and six months ended June 30, 2013 and provided an update on research and development.

Prothena reported a net loss of $11.3 million and $20.3 million for the second quarter and first six months of 2013, respectively, as compared to a net loss of $9.7 million and $20.5 million for the second quarter and first six months of 2012, respectively. Net loss per share for the second quarter and first six months of 2013 was $0.64 and $1.15, respectively, as compared to a net loss per share of $0.67 and $1.42 for the second quarter and first six months of 2012, respectively. As of June 30, 2013, Prothena had $112.5 million in cash and cash equivalents and no outstanding debt. These figures should be read in connection with "Second Quarter and First Six Months of 2013 Financial Results and 2013 Guidance" below.

"Prothena targets proteins in novel ways to resolve unmet clinical needs in patients. We were productive in the second quarter as we continued to advance our pipeline of novel therapeutic antibodies," said Dale Schenk, PhD, President and Chief Executive Officer of Prothena. "Our lead candidate for amyloidosis, NEOD001, entered the clinic during the quarter. We are pleased with patient enrollment to date and remain on track to announce results from our Phase 1 trial of NEOD001 in AL amyloidosis during 2014. Our Parkinson's disease candidate, PRX002, is also moving forward as planned with IND enabling toxicology studies initiated in the quarter."

"Our strong balance sheet continues to provide the financial resources to progress on all three of our lead programs, NEOD001, PRX002, and PRX003-which targets inflammatory disease and metastatic cancers," added Dr. Schenk.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs